Midatech Pharma Share Discussion Threads

[zen12] 17/9/2021 10:05

Excellent results...revenue more than doubled, research costs halved in 2, admin expenses reduced 44%!!Commenting, Stephen Stamp, CEO and CFO of Midatech said: "We are pleased to report good progress throughout the Company and an expanded and exciting pipeline of programmes and opportunities. The disruption and costs of the restructuring in 2020 are now behind us. The first half of 2021 has been highly productive with three potentially viable Q-Sphera formulations, one internal and two for a collaboration partner. We believe the breakthrough data on the encapsulation of a protein could prove to be a very significant opportunity for Midatech."

[jaforsadi] 17/9/2021 10:02

Do you think they have something up their sleeve hence the comment today about "Breakthrough data on the encapsulation of a protein could prove to be a very significant opportunity for midatech"They could release something on Monday before the webinar.

[babbler] 17/9/2021 09:55

Yes and presentation Monday during USA opening hours. 5pm UK time

[jaforsadi] 17/9/2021 09:49

Bit of muted response but usual from uk marketsIf USA likes it and booms there then this will follow here

[babbler] 17/9/2021 09:46

Funded to 2023

[babbler] 17/9/2021 09:37

Overall, we are pleased with the progress we have made in the first half of 2021. We have moved forward our R&D pipeline and created several opportunities for licensing. Our current funding position buys us time and flexibility to convert opportunities into licenses and we are fully focused on meeting that challenge over the coming months.

[david gruen] 17/9/2021 09:33

Midatech Pharma PLC

17 September 2021

17 September 2021

Midatech Pharma Plc


Interim results for the six months ended 30 June 2021

Midatech Pharma PLC (AIM: MTPH.L; NASDAQ: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its unaudited interim results for the six months ended 30 June 2021.

OPERATIONAL HIGHLIGHTS

On 17 June 2021, the Company announced significant progress across a number of R&D programmes including:

Q-Sphera

-- Breakthrough data on the successful encapsulation of an exemplar monoclonal antibody (mAb);
-- The delivery of proof of concept formulations of MTX214 and MTX216 to the Company's collaboration partner for the partner's in vivo studies; and

-- The successful development of MTD211, a long-acting formulation of brexpiprazole which, in in vivo studies, demonstrated therapeutic blood levels over a period of three months.

MTX110

-- Demonstration, in vitro, of the potency of MTX110 in four patient-derived Glioblastoma cell lines.

FINANCIAL HIGHLIGHTS (including post period end)


-- Total revenue in H1 2021 was GBP0.40m (1H20: GBP0.17m).
Total revenue represents income from R&D collaborations
plus grant revenue.
-- Research and development costs decreased by 50% to GBP2.01m
(1H20: GBP3.99m) as a result of the termination of MTD201
and focus on multiple earlier stage programmes.
-- Administrative expenses decreased 44% to GBP1.64m (1H20:
GBP2.93m) due to expenses incurred in connection with
the Strategic Review and restructuring in the prior period.
-- Net cash used in operating activities (after changes in
working capital) in 1H21 was GBP3.11m, compared with GBP7.09m
in 1H20.
-- In July, post period end, the Company raised GBP10.0m
before expenses in an UK Placing of 35.1m ordinary shares
at GBP0.285 per share.
-- The cash balance on 30 June 2021 was GBP4.20m.

.

Commenting, Stephen Stamp, CEO and CFO of Midatech said : "We are pleased to report good progress throughout the Company and an expanded and exciting pipeline of programmes and opportunities. The disruption and costs of the restructuring in 2020 are now behind us. The first half of 2021 has been highly productive with three potentially viable Q-Sphera formulations, one internal and two for a collaboration partner. We believe the breakthrough data on the encapsulation of a protein could prove to be a very significant opportunity for Midatech."

The Company will be hosting a webinar at 5.30pm BST / 12.30pm EST on Monday 20 September 2021. The webinar is open to all existing and potential shareholders and those interested in attending may register via the following link where, following registration, they will be provided with access details:

hxxps://us02web.zoom.us/webinar/register/WN_vLpYaALlRYqUXveBsffy7w

[jaforsadi] 17/9/2021 08:51

Yeah think they will coincide with USA opening. Sp has been flat for over 6 weeks. Placing done at 28.5pMust be time for a significant riseI'm thinking a possibility to 35-40p if results are good.

[babbler] 17/9/2021 08:45

Results were meant to be at 7am. Maybe when USA opens.

[jaforsadi] 17/9/2021 08:38

Sp has been pretty flat and some are already selling before results. USA could love it and it goes boom

[babbler] 17/9/2021 08:24

I'm expecting it will be an excellent share to hold for next year at least.

[kingston78] 17/9/2021 08:18

Chart wise a little movement upwards bodes well for the beginning of another uptrend.

[jaforsadi] 17/9/2021 08:08

I've bought a few yesterday What's your expectation babbler on this.

[babbler] 17/9/2021 08:02

No results. They must be hung over from opening ceramony lol

[babbler] 16/9/2021 10:02

https://mobile.twitter.com/BabblerBestBets/status/1438421600932671489

[babbler] 16/9/2021 10:02

Well someone took 50k shares on open clearly confident here.

[kingston78] 16/9/2021 09:40

I note that the share price has stabilised at around 25-26 p and it is actually below the recent placing price. I suspect that a reasonably encouraging news will propel the share price upwards through the 30 p barrier, leading to 40 p.

[kingston78] 14/9/2021 15:18

Hi Babbler, do you expect an encouraging update?

[babbler] 14/9/2021 12:11

Friday update due. Hopefully run to it

[yus777] 13/9/2021 10:51

strong buy 25p support win win situation

[kingston78] 08/9/2021 10:52

This board has gone quiet. Does anyone have any news on the company's business development? Its share price is not going anywhere at present and I wonder why.

[david gruen] 31/8/2021 12:17

First stop should be 250p, we have to let the big boys accumulate first though.

[yus777] 31/8/2021 12:17

level 2 firming

[yus777] 31/8/2021 12:16

1st stop 29-30p